"Digital health consulting" is one of those labels that sounds specific and isn't. Depending on who is selling it, it can mean product design, clinical-trial support, regulatory filings, EHR integration, marketing, or fundraising help. A health-tech company that goes looking for it without first deciding which decision is actually stuck tends to buy whichever service the firm in the room happens to offer.
The more useful starting point is the structural problem every digital-health company shares: it has to prove clinical value and a viable business model at the same time, in a market where the person who uses the product, the organization that buys it, and the party that pays for it are often three different entities with three different sets of incentives. Most of what good digital health strategy work does is resolve some piece of that problem. Below are the four pieces that come up most often, what each one calls for, and where outside help earns its place versus where it doesn't.
The four decisions hiding under one label
1. Who actually pays, and why
The most common failure pattern in the sector is a product with real engagement and no revenue model, because engagement was assumed to convert on its own. It rarely does. The patient who uses the product is usually not the one holding the budget, and the budget holder (an employer, a health system, or a health plan) is buying a different outcome than the patient experiences: lower cost, better throughput, a quality measure, a retention benefit.
The strategic work is naming the payer, naming the outcome that payer is actually buying, and redesigning the pitch, the pricing logic, and sometimes the product around that outcome rather than around the user experience alone. This is a strategy decision before it is a sales one, and it is the decision most worth getting right first, because every other choice below depends on it.
2. Picking the wedge: reimbursement, employer, or health system
There are usually three viable paths into the market: a reimbursement pathway, an employer or benefits channel, or a direct enterprise sale to health systems. Each one has a different sales cycle, a different evidence bar, a different buyer, and a different kind of team required to win it. Companies that try to pursue all three at once tend to underfund each of them and win none.
Choosing the wedge is a deliberate narrowing decision, and it echoes something we say about professional firms as well: the firms that raise fees fastest don't offer more services; they narrow what they offer and own it. The same logic holds for a digital-health company choosing its first market. The work is comparing the three paths honestly against the company's current evidence, cash runway, and team, and committing to one.
3. Sequencing evidence to the buying decisions it has to clear
Without credible outcomes evidence, enterprise and payer doors stay closed. But evidence is expensive and slow to generate, so the question is not just "do we need evidence" but "which evidence, for which buyer, in what order." A study designed to satisfy a health-system clinical committee may not answer the cost question an employer's benefits team will ask, and vice versa.
Treating evidence as a commercial asset as well as a clinical one, and sequencing it to the buying decisions on the chosen wedge, is strategy work. Designing and running the studies themselves is not; that belongs to the company's clinical team and its research partners.
4. Building the data and compliance posture the buyer will check
Any product that handles patient data inherits real privacy and security obligations. HIPAA's Breach Notification Rule, for example, gives a covered entity no more than 60 days after discovering a breach to notify the patients affected, and a vendor handling that data for a health system or plan sits inside that chain. That is why enterprise buyers increasingly run security and compliance review as a gate before a contract, not after it. A company that treats this as a late-stage paperwork exercise usually discovers it as a stalled deal.
The strategic question is how the data architecture, governance, and vendor posture should be designed so that they clear the reviews the target buyer will actually run, and so that the data the product generates can later support the outcomes story. That is partly a data strategy question and partly a compliance one.
What to ask before you scope the engagement
Two questions separate an engagement that will do real work from one that will produce a slide deck. First: does the proposed scope name which of the four decisions above it is actually solving? "Digital health strategy" pitched without committing to one of them is being scoped by the seller, not the buyer. Second: does the recommendation account for all three parties (user, buyer, and payer), or only the one the firm is most comfortable talking to? A go-to-market plan that optimizes for the user and ignores who pays is the most common way good products stall.
It is also worth being explicit about what an outside strategy advisor should not be asked to do here. Validating clinical efficacy, running trials, and preparing regulatory submissions belong to the company's clinical and regulatory teams and their specialist partners. The strategic work sits around that core: deciding what the evidence needs to prove, to whom, and in what order.
Where this fits
Choosing the customer, the wedge, and the business model is strategy consulting work. Turning that choice into an enterprise or employer motion that closes is sales consulting, and testing the reimbursement path and business model before scaling spend is what innovation consulting is for. We work through these dynamics in more detail on the digital health industry page, and the payer side of the same three-party market is covered in what health plans actually need from payer consulting. If the stuck decision is how to bring AI into a clinical setting, sequencing AI adoption in healthcare takes that up directly.
If you are trying to work out which of the four decisions above is the one actually holding your company back, that is a scoping conversation worth having before you hire anyone. Start one here: we would rather help you name the real problem than sell you a generic digital-health engagement.